Alexion Pharmaceuticals Launches New Microarray Subsidiary | GenomeWeb

NEW YORK, Oct 25 – Alexion Pharmaceuticals of Boston, Mass., has become the latest in a string of companies to enter the microarray market with its announcement on Wednesday that it planned to spin off a new company, Arradial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.